Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis
Authors:
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The risk and burden of vertebral fractures in SwedenOsteoporosis International, 2003
- Mortality after osteoporotic fracturesOsteoporosis International, 2003
- Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trialBone, 2003
- Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE StudyOsteoporosis International, 2002
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002
- Acute and Long-Term Increase in Fracture Risk after Hospitalization for Vertebral FractureOsteoporosis International, 2001
- Health-Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral FracturesJournal of Bone and Mineral Research, 2000
- Excess Mortality Following Vertebral FractureJournal of the American Geriatrics Society, 2000
- Vertebral Fractures and Mortality in Older WomenArchives of internal medicine (1960), 1999
- Perspective how many women have osteoporosis?Journal of Bone and Mineral Research, 1992